# A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

> **NCT04551079** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 19 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** TAK-994
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04551079
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-23
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551079, "A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04551079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*